WAVE LIFE SCIENCES LTD (WVE)

Company Profile

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. The company employs 266 full-time employees The company went IPO on 2015-11-11. The firm is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. The company is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

Company Info

WAVE LIFE SCIENCES LTD

7 Straits View, #12-00, Marina One East Tower

Singapore 018936

P: 6562363388

CEO: Paul B. Bolno

Employees: 267

Website: https://www.wavelifesciences.com/